File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Temozolomide in the treatment of recurrent malignant glioma in Chinese patients

TitleTemozolomide in the treatment of recurrent malignant glioma in Chinese patients
Authors
KeywordsAstrocytoma
Brain neoplasms
Disease-free survival
Glioblastoma
Neoplasm recurrence
Issue Date2005
Citation
Hong Kong Medical Journal, 2005, v. 11, n. 6, p. 452-456 How to Cite?
AbstractObjective. To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma. Design. Open-label trial. Setting. University teaching hospital, Hong Kong. Patients. Twenty-two patients had been enrolled in the study since 2001. Patients had to show unequivocal evidence of tumour recurrence or progression on gadolinium-enhanced magnetic resonance imaging after failing conventional radiotherapy and surgery for initial disease. Histology reviewed by a neuropathologist was required to show anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma) or glioblastoma multiforme. Interventions. Patients were treated with temozolomide (200 mg/m2 per day for the first 5 days of a 28-day cycle for four cycles) and monitored clinically every month and radiologically (gadolinium magnetic resonance imaging) at 6 months. Main outcome measures. Six-month progression-free survival and objective response rate. Results. Twenty-two patients with recurrent malignant glioma were recruited between January 2001 and July 2004. Progression-free survival at 6 months was 54.5%. The mean progression-free survival for all patients was 7.2 months. The objective response rate, determined by gadolinium magnetic resonance imaging, was 9% for patients demonstrating a complete or partial response and a further 45% for patients demonstrating stable disease. Temozolomide was well tolerated orally with minimal adverse events. Conclusion. Preliminary results showed that temozolomide had an acceptable safety profile and anti-tumour activity in recurrent malignant glioma in local Chinese population. The results were comparable with those of western studies.
Persistent Identifierhttp://hdl.handle.net/10722/325111
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.261

 

DC FieldValueLanguage
dc.contributor.authorChan, D. T.M.-
dc.contributor.authorPoon, W. S.-
dc.contributor.authorChan, Y. L.-
dc.contributor.authorNg, H. K.-
dc.date.accessioned2023-02-27T07:29:49Z-
dc.date.available2023-02-27T07:29:49Z-
dc.date.issued2005-
dc.identifier.citationHong Kong Medical Journal, 2005, v. 11, n. 6, p. 452-456-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/325111-
dc.description.abstractObjective. To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma. Design. Open-label trial. Setting. University teaching hospital, Hong Kong. Patients. Twenty-two patients had been enrolled in the study since 2001. Patients had to show unequivocal evidence of tumour recurrence or progression on gadolinium-enhanced magnetic resonance imaging after failing conventional radiotherapy and surgery for initial disease. Histology reviewed by a neuropathologist was required to show anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma) or glioblastoma multiforme. Interventions. Patients were treated with temozolomide (200 mg/m2 per day for the first 5 days of a 28-day cycle for four cycles) and monitored clinically every month and radiologically (gadolinium magnetic resonance imaging) at 6 months. Main outcome measures. Six-month progression-free survival and objective response rate. Results. Twenty-two patients with recurrent malignant glioma were recruited between January 2001 and July 2004. Progression-free survival at 6 months was 54.5%. The mean progression-free survival for all patients was 7.2 months. The objective response rate, determined by gadolinium magnetic resonance imaging, was 9% for patients demonstrating a complete or partial response and a further 45% for patients demonstrating stable disease. Temozolomide was well tolerated orally with minimal adverse events. Conclusion. Preliminary results showed that temozolomide had an acceptable safety profile and anti-tumour activity in recurrent malignant glioma in local Chinese population. The results were comparable with those of western studies.-
dc.languageeng-
dc.relation.ispartofHong Kong Medical Journal-
dc.subjectAstrocytoma-
dc.subjectBrain neoplasms-
dc.subjectDisease-free survival-
dc.subjectGlioblastoma-
dc.subjectNeoplasm recurrence-
dc.titleTemozolomide in the treatment of recurrent malignant glioma in Chinese patients-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid16340021-
dc.identifier.scopuseid_2-s2.0-30944434401-
dc.identifier.volume11-
dc.identifier.issue6-
dc.identifier.spage452-
dc.identifier.epage456-
dc.identifier.eissn1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats